Sutro Biopharma, Inc. (STRO) Stock Price

STROStock

$21.44+138.81%52W

Market Cap$355.50M

P/E—

PEG Ratio—

Div yield—

Beta1.47

STRO Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)6.31%

Price vs S&P 500 (4W)-16.71%

VGM Score51.13

Book Value / Share (Quarterly)$0.53

P/TBV (Annual)0.69x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)14.78%

Cash Flow / Share (Quarterly)$-9.18

Price vs S&P 500 (YTD)65.14%

Net Profit Margin (TTM)-154.21%

EPS (TTM)$-16.35

10-Day Avg Trading Volume0.42M

EPS Excl Extra (TTM)$-16.35

Revenue Growth (5Y)19.13%

EPS (Annual)$-22.49

ROI (Annual)-100.91%

Net Profit Margin (5Y Avg)-193.80%

Cash / Share (Quarterly)$12.23

Revenue Growth QoQ (YoY)-16.53%

ROA (Last FY)-109.93%

Revenue Growth TTM (YoY)49.94%

EBITD / Share (TTM)$-11.64

ROE (5Y Avg)-137.55%

Operating Margin (TTM)-119.98%

Cash Flow / Share (Annual)$-20.84

P/B Ratio8.18x

P/B Ratio (Quarterly)3.45x

Net Income / Employee (Annual)$-1,394,800

EV / Revenue (TTM)5.18x

Net Interest Coverage (TTM)-14.06x

ROA (TTM)-69.20%

EPS Incl Extra (Annual)$-22.49

Current Ratio (Annual)2.01x

Quick Ratio (Quarterly)3.04x

3-Month Avg Trading Volume0.33M

52-Week Price Return138.81%

Revenue / Employee (TTM)$727,100

Tangible BV / Share (Quarterly)$1.84

P/S Ratio (Annual)3.51x

Asset Turnover (Annual)0.59x

52-Week High$43.85

Operating Margin (5Y Avg)-189.28%

EPS Excl Extra (Annual)$-22.49

CapEx CAGR (5Y)-24.97%

26-Week Price Return17.56%

Quick Ratio (Annual)1.94x

13-Week Price Return-33.08%

Total Debt / Equity (Annual)4.05x

Current Ratio (Quarterly)3.12x

Enterprise Value$515.50M

Revenue / Share Growth (5Y)55.85%

Asset Turnover (TTM)0.45x

Book Value / Share Growth (5Y)5.00%

Revenue / Employee (Annual)$748,100

Pretax Margin (Annual)-186.55%

Cash / Share (Annual)$16.48

3-Month Return Std Dev89.04%

Net Income / Employee (TTM)$-1,121,200

ROE (Last FY)-509.99%

Net Interest Coverage (Annual)-5.34x

EPS Basic Excl Extra (Annual)$-22.49

P/FCF (TTM)16.66x

Receivables Turnover (TTM)7.65x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-16.35

Receivables Turnover (Annual)16.28x

ROI (TTM)-223.84%

P/S Ratio (TTM)3.61x

Pretax Margin (5Y Avg)-189.95%

Revenue / Share (Annual)$12.06

Tangible BV / Share (Annual)$3.77

Price vs S&P 500 (52W)120.50%

Year-to-Date Return77.10%

5-Day Price Return-7.03%

EPS Normalized (Annual)$-22.49

ROA (5Y Avg)-50.31%

Net Profit Margin (Annual)-186.45%

Month-to-Date Return-15.23%

Cash Flow / Share (TTM)$-2.80

EBITD / Share (Annual)$-17.77

Operating Margin (Annual)-154.53%

LT Debt / Equity (Annual)4.05x

ROI (5Y Avg)-46.86%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-16.35

P/TBV (Quarterly)1.33x

P/B Ratio (Annual)3.40x

Pretax Margin (TTM)-154.32%

Book Value / Share (Annual)$5.40

Price vs S&P 500 (13W)-35.88%

Beta1.47x

P/FCF (Annual)32.38x

Revenue / Share (TTM)$7.61

ROE (TTM)-223.84%

52-Week Low$7.15

vGradeC

gGradeC

mGradeC

vgmGradeC

STRO Earnings Surprise History

Q2 25-1.40est. -3.82

Q3 25-5.57est. -3.55

Q4 25-4.88est. -4.43

Q1 26-2.94est. -3.21

Q2 26-2.31est. -2.27

STRO Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.00

4.10

4.11

Industry Peers — Biological Products(183)

Symbol	Value Score	Growth Score	Momentum Score	Price
STROSutro Biopharma, Inc.	C	C	C	$21.44
AMGNAmgen Inc	C	C	B	$442.24
GILDGilead Sciences Inc	C	B	B	$148.77
MRNAModerna, Inc. Common Stock	D	C	A	$158.83
ARGXargenx SE American Depositary Shares	D	A	B	$1019.49
RVMDRevolution Medicines, Inc. Common Stock	F	—	A	$211.38
BIIBBiogen Inc. Common Stock	C	D	B	$220.77
BNTXBioNTech SE American Depositary Share	C	C	B	$114.05
NBIXNeurocrine Biosciences Inc	C	B	C	$153.37
EXELExelixis Inc	C	B	B	$56.72
HALOHalozyme Therapeutics, Inc.	C	B	A	$109.32
TECHBio-Techne Corp.	D	C	B	$72.33
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	$356.19
KYMRKymera Therapeutics, Inc. Common Stock	D	B	B	$126.64
RGENRepligen Corp	D	C	A	$181.69
APGEApogee Therapeutics, Inc. Common Stock	—	—	A	$134.85
TWSTTwist Bioscience Corporation Common Stock	D	B	A	$151.42
PCVXVaxcyte, Inc. Common Stock	—	—	B	$61.09
QGENQIAGEN N.V.	C	C	C	$43.65
IMVTImmunovant, Inc. Common Stock	—	—	B	$43.50
IBRXImmunityBio, Inc. Common Stock	F	A	C	$8.19
SRRKScholar Rock Holding Corporation Common Stock	F	—	B	$58.25
CGONCG Oncology, Inc. Common stock	F	A	A	$78.95
CRSPCRISPR Therapeutics AG	D	B	B	$60.90
RLAYRelay Therapeutics, Inc. Common Stock	F	D	A	$20.57
ADPTAdaptive Biotechnologies Corporation Common Stock	D	B	A	$26.25
DNLIDenali Therapeutics Inc. Common Stock	F	—	B	$24.93
IOVAIovance Biotherapeutics, Inc. Common Stock	C	B	A	$8.44
BEAMBeam Therapeutics Inc. Common Stock	C	B	B	$31.03
TARSTarsus Pharmaceuticals, Inc. Common Stock	D	A	B	$71.45
BCRXBioCryst Pharmaceuticals Inc	B	A	B	$9.83
KODKodiak Sciences Inc Common Stock	—	—	B	$39.46
COAGHemab Therapeutics Holdings, Inc. Common Stock	—	—	B	$49.65
MESOMesoblast Limited American Depositary Shares	D	B	C	$17.19
VCELVericel Corporation	D	B	C	$43.22
ADMAADMA Biologics, Inc.	C	C	C	$9.72
TSHATaysha Gene Therapies, Inc. Common Stock	F	B	B	$6.20
IMCRImmunocore Holdings plc American Depositary Shares	D	B	B	$37.40
RXRXRecursion Pharmaceuticals, Inc. Class A Common Stock	D	C	C	$3.56
VIRVir Biotechnology, Inc. Common Stock	B	B	B	$10.71
INBXInhibrx Biosciences, Inc. Common Stock	D	C	B	$122.72
ALVOAlvotech Ordinary Shares	C	D	B	$5.05
MAZEMaze Therapeutics, Inc. Common Stock	—	—	B	$30.42
NVAXNovavax Inc	B	D	C	$9.44
REPLReplimune Group, Inc.	—	—	A	$15.80
SLBTSL Science Holding Limited Ordinary Shares	—	—	F	$2.64
MGTXMeiraGTx Holdings plc Ordinary Shares	D	C	A	$14.92
VORVor Biopharma Inc. Common Stock	—	—	B	$24.01
CGEMCullinan Therapeutics, Inc. Common Stock	—	—	A	$22.95
IMTXImmatics N.V. Ordinary Shares	C	D	C	$9.24
ODTXOdyssey Therapeutics, Inc. Common Stock	—	C	A	$26.23

About Sutro Biopharma, Inc.

Sutro Biopharma is a clinical-stage biopharmaceutical company developing protein therapeutics for cancer and autoimmune disorders using its proprietary XpressCF cell-free protein synthesis platform. Lead programs include STRO-001 for multiple myeloma and non-Hodgkin lymphoma, and STRO-002 for ovarian and endometrial cancers, with additional candidates in development.